Puma Biotechnology, Inc. (PBYI - Free Report) was a big mover last session, as its shares rose over 30% on the day. The move came after the Food and Drug Administration (FDA) advisory committee voted 12-4 recommending that Puma's breast-cancer drug neratinib be approved. This also led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 95% in the past one-month time frame.
The company has seen two positive estimate revisions in the last 30 days, while its Zacks Consensus Estimate moved higher over the same time frame, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.
Puma Biotechnology currently carriess a Zacks Rank #2 (Buy), while its Earnings ESP is 0.00%.
Another top ranked stock from the Medical - Biomedical and Genetics space is VIVUS, Inc. , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is PBYI going up? Or down? Predict to see what others think: Up or Down
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Puma Biotechnology, Inc. (PBYI - Free Report) was a big mover last session, as its shares rose over 30% on the day. The move came after the Food and Drug Administration (FDA) advisory committee voted 12-4 recommending that Puma's breast-cancer drug neratinib be approved. This also led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 95% in the past one-month time frame.
The company has seen two positive estimate revisions in the last 30 days, while its Zacks Consensus Estimate moved higher over the same time frame, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.
Puma Biotechnology currently carriess a Zacks Rank #2 (Buy), while its Earnings ESP is 0.00%.
Another top ranked stock from the Medical - Biomedical and Genetics space is VIVUS, Inc. , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is PBYI going up? Or down? Predict to see what others think: Up or Down
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on PBYI - FREE